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Within I-MOVE (European programme to monitor seasonal and 
pandemic influenza vaccine effectiveness (IVE)) five countries 
conducted IVE pilot case-control studies in 2008-9. One hundred 
and sixty sentinel general practitioners (GP) swabbed all elderly 
consulting for influenza-like illness (ILI). Influenza confirmed cases 
were compared to influenza negative controls. We conducted a 
pooled analysis to obtain a summary IVE in the age group of ≥65 
years. We measured IVE in each study and assessed heterogeneity 
between studies qualitatively and using the I2 index. We used 
a one-stage pooled model with study as a fixed effect. We 
adjusted estimates for age-group, sex, chronic diseases, smoking, 
functional status, previous influenza vaccinations and previous 
hospitalisations. The pooled analysis included 138 cases and 189 
test-negative controls. There was no statistical heterogeneity (I2=0) 
between studies but ILI case definition, previous hospitalisations 
and functional status were slightly different. The adjusted IVE 
was 59.1% (95% CI: 15.3-80.3%). IVE was 65.4% (95% CI: 
15.6-85.8%) in the 65-74, 59.6% (95% CI: -72.6 -90.6%) in 
the age group of ≥75 and 56.4% (95% CI: -0.2-81.3%) for A(H3). 
Pooled analysis is feasible among European studies. The variables 
definitions need further standardisation. Larger sample sizes are 
needed to achieve greater precision for subgroup analysis. For 2009-
10, I-MOVE will extend the study to obtain early IVE estimates in 
groups targeted for pandemic H1N1 influenza vaccination.
Introduction
The influenza virus has a high genetic mutation rate that 
frequently determines antigenic drifts and occasionally antigenic 
shifts. To achieve a good match between circulating and vaccine 
viruses, the composition of the vaccine has to be reformulated 
each season based on the recommendations of the World Health 
Organization (WHO) Global Influenza Surveillance Network [1]. 
Therefore, influenza vaccine effectiveness (IVE) can vary from year 
to year according to the degree of match between the selected 
vaccine strains and those actually circulating. Hence, IVE should 
be measured and monitored every year. In a pandemic situation, 
strain specific vaccines become available only four to six months 
after beginning the development of the vaccine. Consequently, 
when the vaccines start to be administered, the virus is already 
circulating and IVE results are needed rapidly. In addition, vaccine 
availability is likely to increase over time according to the speed 
of vaccine production and the licensing of additional vaccines, 
meaning that IVE measurements need to be repeated over time 
during the pandemic. 
Many factors affect IVE in observational studies. IVE estimates 
vary according to the specificity of the outcome, the influenza 
incidence, the population targeted for vaccination and the 
confounding factors taken into account.  Many of the case-control 
studies reported in the literature measured IVE against clinical 
outcomes (i.e. hospitalisations for pneumonia or influenza, acute 
respiratory infections, influenza-like illness (ILI)). Clinical outcomes 
for influenza are non-specific and likely to underestimate the IVE 
[2]. To minimise bias, laboratory-confirmed influenza is now being 
used as outcome in case-control studies in Canada, Australia and 
the USA [3-5]. 
Confounding affects IVE observational studies. IVE is 
underestimated when individuals at higher risk of acquiring 
influenza are more likely to be vaccinated than individuals at lower 
risk (negative confounding by indication) [6,7]. IVE is overestimated 
if individuals more cautious about their health and at lower risk 
of acquiring influenza are more likely to be vaccinated (positive 
confounding due to healthy vaccinee effect) [7,8].
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In general practitioners (GP) based case-control studies, 
individuals who use health services more often are more likely to 
be vaccinated and more likely to consult their GP with influenza 
symptoms. Vaccinated individuals with influenza symptoms will 
have a higher probability of being included in the study than 
vaccinated individuals with no influenza symptoms. This would 
underestimate the IVE. To control for health seeking behaviour, 
recent studies suggested comparing individuals who consult for 
ILI and are influenza positive to individuals consulting for ILI who 
test negative for influenza (test-negative controls) [3-5;9]. The 
assumption is that test-negative controls have the same vaccination 
coverage as the source population giving rise to the influenza cases 
detected at the GP practice.
I-MOVE started in 2007 with the aim to measure IVE against 
seasonal and pandemic influenza in the European Union (EU) and 
the European Economic Area (EEA). Two cohort and five case-control 
studies to measure IVE were piloted in the 2008-9 season. In order 
to develop a sustainable system, the studies were conducted in 
the framework of existing GP-based influenza sentinel surveillance 
systems. All the country teams conducting I-MOVE pilot studies are 
members of the European Influenza Surveillance Network (EISN) 
(the successor of the Commission-funded network, EISS). EISN 
collects and exchanges timely information on influenza activity 
in Europe [11]. National Reference Laboratories participating in 
EISN are evaluated periodically through external inter-laboratory 
quality control assessments. All the EU Member States recommend 
seasonal vaccine for the elderly either defined as 65 years old and 
older or as 60 years old and older [12].
In the pilot case-control studies, we measured IVE against 
laboratory-confirmed influenza and collected variables to control 
for positive and negative confounding in the analysis. We restricted 
the study population to community-dwelling elderly. To increase the 
precision of the estimates and to provide a summary IVE for the five 
studies, we explored the feasibility of conducting a pooled analysis. 
We present here the pooled results of the pilot case-control studies 
conducted in Denmark, Hungary, Portugal, Romania, and Spain. 
We assumed that if the pooled case-control design was feasible for 
seasonal vaccine, the study population could later be expanded to 
include the age groups targeted for the pandemic vaccine. 
Methods
The study population consisted of community-dwelling elderly 
living in selected sentinel GP practice catchment areas in the 
five participating European countries. Age groups included were 
60 year-olds and older in Hungary and 65 year–olds and older in 
the other four countries. Participating sentinel GPs swabbed all 
community-dwelling elderly individuals consulting for ILI during 
2008-9 influenza season.
For the first time, in Denmark, Hungary, and Romania sentinel 
GPs used the EU ILI case definition [13]. In Spain, the ILI EU case 
definition was used with an additional stated criterion “without any 
other suspected diagnosis”. In Portugal, ILI was defined as in the 
routine sentinel surveillance, according to GPs´ criteria. Clinical 
symptoms were collected for all ILI cases. 
ILI patients were not eligible for the study if they were 
institutionalised, had evidence of dementia, did not speak the 
local language or refused participation.
A case of influenza was defined as an ILI patient who was swabbed 
and tested positive for influenza using real-time polymerase chain 
reaction (RT-PCR) or culture. Test-negative controls included in 
the five studies were ILI patients who were swabbed and tested 
negative for influenza.
To check if vaccination coverage observed among ILI patients 
testing negative for influenza was different from that observed in 
other potential control groups, we measured vaccination coverage 
among systematic samples of patients from participating GPs who 
had not had ILI since the beginning of the influenza season (non-ILI 
controls; up to two controls selected around the time of occurrence 
of a case) (Hungary, Portugal, Spain), in the community (Denmark, 
Portugal) and in the participating GPs’ catchment area (Hungary, 
Romania, Spain). 
A person was considered vaccinated if s/he had received the 
2008-9 influenza vaccine more than 14 days before date of onset 
of ILI symptoms or of selection as a control.
The minimum set of common confounding variables for the five 
countries included age, sex, presence of chronic conditions and 
their respective severity measured in number of hospitalisations 
for the chronic diseases in the previous 12 months or any 
hospitalisation in the previous 12 months (Hungary and Portugal), 
smoking history (none, past, current smoker), functional status 
(help for bathing and/or help for walking), and influenza vaccination 
in the previous two seasons.
All ILI patients had a nasal or throat swab taken, which was 
tested for influenza at the respective countries’ National Influenza 
Reference Laboratory (in Spain, all laboratories integrated in the 
Spanish Influenza Sentinel Surveillance System) using RT-PCR 
techniques and/or culture. In each country, all or a subset of 
influenza isolates were antigenically characterised. Laboratory viral 
detection, typing, subtyping and variant analysis performed in each 
of the National Reference Laboratories are described elsewhere 
[14].
The sentinel GPs carried out face-to-face interviews with 
ILI patients and non-ILI control patients using country-specific 
standardised questionnaires. Trained interviewers conducted 
telephone interviews with community controls using a standardised 
questionnaire in Denmark and Portugal. Each country study team 
entered and validated data. 
A previously agreed minimum dataset for pooling, including 
information on case or control status and exposure status and 
several covariates, was sent to EpiConcept, the I-MOVE coordination 
focal point. EpiConcept checked the data again for inconsistencies, 
outliers and logical errors and conducted the pooled analysis.
We created a common restricted dataset of ILI patients meeting 
the EU case definition, older than 64 years and with a delay 
between onset of symptoms and swabbing of less than eight days. 
For each of the country specific datasets, we excluded the controls 
identified before the week of the first case and after the week of 
the last case, in order to include only ILI cases within the influenza 
season. 
IVE estimates were obtained using the formula: 1- odds ratio, 
with 95% exact confidence intervals (CI) [10,15].
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We computed study specific crude IVE and adjusted for the 
pre-defined set of confounders (including age, sex, chronic 
disease, smoking, previous influenza vaccination and functional 
status) where possible, using logistic regression. We evaluated 
heterogeneity between studies qualitatively by assessing the 
standardisation of the case and covariate definitions. We evaluated 
statistical heterogeneity using the Q-test and the I2 index [16,17]. 
To estimate a pooled IVE, we used a one-stage method with study 
as fixed effect in the model. Results were stratified according to 
influenza strain and two age groups: 65-74 and >74 years.
According to country specific requirements for ethical approval, 
all participants provided oral or written consent. 
F i g u r e  1
Influenza-like illness (ILI) incidence (cases per 100,000 population) reported by the national influenza sentinel surveillance 
systems in Denmark, Hungary, Portugal, Romania, and Spain, influenza season 2008-9*
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T a b l e  1
General practitioner (GP) participation and influenza-like illness (ILI) cases recruitment by study, Denmark, Hungary, 
Portugal, Romania, and Spain, influenza season 2008-9
Study Number of GPs accepting to participate
Number of GPs recruiting 
at least one ILI patient (%)
Number of ILI patients 
recruited by GPs
Number of ILI patients 
positive to influenza (%)
Number of non-
ILI GP patients
Number of 
community controls
Denmark 40 29 (73) 63 25 (40) N/A 80
Hungary 50 27 (54) 144 45 (32) 89 N/A
Portugal 42   9 (21) 42 15 (36) 40 136
Romania 47 28 (60) 103 30 (29) N/A N/A
Spain 164 67 (40) 103 44 (43) 88 N/A
Total 343 160 (47) 455 159 (35) 217 216
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T a b l e  2
Influenza cases and test-negative controls by study and characteristic, Denmark, Hungary, Portugal, Romania, and Spain, 
influenza season 2008-9  
Characteristics Country ILI patients p
  Influenza cases Test-negative controls  
Interval from symptom onset to swab sample 
collection (mean in days)
Denmark 3.05 4.25 0.001*
Hungary 2.1 3.08 0.036*
Portugal 1.5 2.33 0.030*
Mean age Portugal 70 75 0.040*
 
Number with characteristic
/ total 
Number with 
characteristic 
/ total 
Any influenza vaccination in past 2 seasons
Portugal 4/14 10/14 0.023**
Spain 28/43 33/36 0.005**
Fever
Denmark 19/20 14/21 0.022**
Romania 30/30 57/68 0.019**
Cough Denmark 20/20 16/21 0.020**
Chronic pulmonary disease Romania 1/30 13/68 0.040**
*Mann-Whitney U test, **Chi square
F i g u r e  2
Diagramme with study exclusion criteria, Denmark, Hungary, Portugal, Romania, and Spain, influenza season 2008-9
Spain: 103 Denmark: 63 Portugal: 42 Romania: 103 Hungary: 144
Original data
Subtracting persons 
aged <65
Hungary: 96
-  48
Denmark: 61
-  2
Subtracting persons 
in residential home
Denmark: 58
-  3
Subtracting persons not 
fulfilling the European 
Union (EU) influenza-
like illness (ILI) case 
definition
Subtracting controls 
outside of weeks of first 
and last case
Spain: 102
-  1
Subtracting persons with an 
interval >7 days between 
symptoms and swabbing
Spain: 101
-  1
Spain:  81
-  20
Denmark: 56
-  2
Denmark: 43
-  13
Portugal: 38
-  4
Portugal: 37
-  1
Portugal: 29
-  8
Romania: 99
-  4
Romania: 98
-  1
Hungary: 93
-  3
Hungary: 78
-  15
Denmark: 41
-  2
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Results
In the participating pilot countries, the 2008-9 seasonal influenza 
epidemic started in Portugal at the end of 2008 (epidemiological 
week 49) and spread to the east of Europe (Hungary) in spring 
2009 (week 4) (Figure 1).   
The duration of the epidemic period ranged from seven weeks 
in Denmark to 13 weeks in Romania. The influenza peaks were 
reached between week 52 in 2008 (Portugal) and week 10 in 
2009 (Romania). 
In the five participating countries, the population was vaccinated 
with a trivalent inactivated influenza vaccine. In the 2008-9 
influenza season, different vaccine brands were used in each of 
the countries.  The number of GPs enrolled in each of the studies 
ranged from 40 in Denmark to 164 in Spain. Overall, 160 GPs 
recruited at least one patient ranging from 21% in Portugal to 73% 
in Denmark (Table 1). GPs swabbed and interviewed a total of 455 
ILI patients. Among them, 159 (35%) were positive for influenza 
(from 29% in Romania to 43% in Spain). The completeness of the 
variables in the returned questionnaires varied from 85% to 100%. 
Among 147 isolates typed before the restriction criteria were 
applied, 131 (89%) were influenza A and 16 (11%) B. Ninety-
five of the A isolates were H3N2. All H3N2 strains genetically 
characterised were A/Brisbane/10/07 similar to the H3N2 vaccine 
component of the 2008-9 northern hemisphere vaccine. The B 
strain included in the 2008-9 vaccine did not match the circulating 
strain. Eight out of the 16 type B isolates were from cases enrolled 
in Hungary. 
After applying the study restriction criteria we included 138 
cases and 189 test-negative controls in the analysis (Figure 2).
T a b l e  4
Country specific and pooled crude and adjusted vaccine effectiveness (VE), Denmark, Hungary, Portugal, Romania, and 
Spain, influenza season 2008-9
 
 
Crude analysis  Adjusted analysis
Variables used for adjustment
N VE 95% CI N VE 95% CI
Country specific 
estimates
Spain 81 80.8 36.0 - 94.2 76 82.9 30.6 - 95.8 age, sex, chronic disease, smoking, functional status
Portugal 29 34.4 -184.3 - 84.9 28 82.3 -70.5 - 98.2 age, sex, chronic disease, smoking
Denmark 41 51.1 -78.2 - 86.6 34 90.9 -43 - 99.4
age, sex, chronic disease, smoking, previous influenza 
vaccination
Romania 98 58.2 -0.8 - 82.6 92 86.8 38.0 - 97.2
age, sex, chronic disease, smoking, previous influenza 
vaccination
 Hungary 78 28.6 -78.6 - 71.5 72 43.6 -119.8 - 85.6
age, sex, chronic disease, smoking, previous influenza 
vaccination
Pooled estimates 65+ 327 55.1 27.8 - 72.1 292 59.1 15.3 – 80.3
study, age, sex, chronic disease, smoking,  previous 
influenza vaccination, functional status, previous 
hospitalisation
65-74 years   196 65.4 15.6 - 85.8
study, sex, chronic disease, smoking, previous 
influenza flu vaccination, functional status, previous 
hospitalisation
75+ years   96 59.6 -72.6 - 90.6
study, sex, chronic disease, smoking, previous 
influenza vaccination, functional status, previous 
hospitalisation
 A(H3) strain    259 56.4 -0.2 - 81.0
study, age, sex, chronic disease, smoking, previous 
influenza vaccination, functional status, previous 
hospitalisation
T a b l e  3
Vaccination coverage for the seasonal 2008-9 influenza vaccine by control group and country study, Denmark, Hungary, 
Portugal, Romania, and Spain, 2008-9
Study Vaccine coverage (%) in ILI positive cases
Vaccine coverage (%) in 
test-negative controls
Vaccine coverage (%) in 
non-ILI GP patients
Vaccine coverage in 
community controls
Vaccine coverage in participating 
GPs catchment area
Denmark 55 71.4 N/A 53.6** N/A
Hungary*** 41.9 48.7 42.7 N/A 38.5
Portugal 42.9 53.3 70 54.4* N/A
Romania 46.7 67.6 N/A N/A 86.9
Spain 61.4 89.2 80.7 N/A 65.3
N/A : not applicable
*Community controls sample selected for national telephone survey (Lisboa: Instituto Nacional de Saúde Dr. Ricardo Jorge. Observátorio Nacional de 
Saúde)
** Community controls randomly selected from the Danish population register
*** Results apply to ages 65 years and above, apart from Hungary where the study was carried out for 60 year-olds and older
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In Romania and Denmark, the proportion of ILI patients 
presenting with fever was higher among cases than among test-
negative controls (Table 2). In Denmark, all of the cases and three 
quarters of the controls had a cough (p=0.02). In Romania, the 
proportion of ILI patients with pulmonary chronic disease was lower 
among cases than among controls (3% vs. 19%).
The mean delay between onset of symptoms and swab collection 
was shorter for cases than for test-negative controls in Portugal, 
Denmark and Romania (Table 2). In Spain and Portugal, the 
proportion of people having received influenza vaccines in at least 
one of the two previous seasons was lower among cases than among 
test-negative controls.
Vaccination coverage among controls varied according to country 
and control group; no specific pattern was identified (Table 3).
The country specific adjusted VE estimates ranged from 43.6% 
(95% CI: -119.8 - 85.6) in Hungary to 90.9% (95% CI: -42.6 - 
99.4) in Denmark (Table 4).  
In terms of heterogeneity between studies, two out of the five 
studies used a different ILI definition. Three variables (number 
of hospitalisations, presence of chronic diseases and functional 
status) were collected differently in the five studies. The Q test 
for heterogeneity was 2.87 (p = 0.579) and the I2 index was 0%.
In the pooled analysis the crude IVE was 55.1% (95% CI: 27.8-
72.1%). The IVE adjusted for study, age, sex, presence of chronic 
conditions, previous hospitalisations, smoking history, functional 
status, and previous influenza vaccination was 59.1% (95% CI: 
15.3-80.3%) (Table 4). 
The adjusted IVE was 65.4% (95% CI: 15.6-85.8%) in the 65-
74 year-olds and 59.6% (95% CI: -72.6 -90.6%) in the age-group 
of ≥75 years. The adjusted IVE against the A(H3) strain was 56.4% 
(95% CI: -0.2-81.0%). 
Discussion
We estimated influenza VE against laboratory-confirmed 
medically attended influenza using test-negative controls, within 
existing sentinel GP networks in five EU countries. The country 
specific and the pooled IVE estimates suggest a protective effect of 
the 2008-9 seasonal vaccine in the elderly population in a year with 
a good match between the seasonal vaccine and the A(H3) strain 
predominantly circulating in Europe [18]. However, the estimates 
have wide confidence intervals.  
The case-control design using test-negative controls was 
performed easily in the framework of the established GP sentinel 
surveillance networks. Participating GPs had previous experience 
in collecting swabs and in completing a form for each patient 
swabbed. Among the GPs who accepted to participate in the study, 
less than half interviewed and swabbed ILI patients. This may 
be explained by the overall low incidence of ILI in the elderly in 
2008-9 [18] rather than a low acceptability of GPs, as swabbing 
and interviewing ILI patients is a simple way of recruiting cases and 
test- negative controls. The questionnaires used for data collection 
were short leading to a high completeness of all variables. At the 
end of the season, the study coordinators in Denmark, Romania, 
and Spain interviewed GPs who participated in the 2008-9 study. 
Most of them (95% in Spain, 78% in Romania, 74% in Denmark) 
would be willing to participate in the study in 2009-10 (data not 
shown).  In 2006 in Denmark (one of the current study sites), 
Mazick et al. showed similar acceptability results following an 
influenza VE case-control study based on the sentinel GP network 
[19]. 
The recruitment procedure minimised selection bias as all ILI 
cases were swabbed.  Furthermore, GPs did not know the case or 
control status when recruiting ILI patients. This was the first season 
in which the EU ILI case definition was introduced into the sentinel 
GP networks. For most ILI patients recruited, the case definition 
was correctly used: of 455 ILI patients reported, only 17 were 
excluded because they did not match the EU ILI case definition. 
However, we cannot rule out that some GPs did not include all 
patients corresponding to the EU case definition. If the sensitivity of 
GPs´ ILI case definition were dependent on the vaccination status, 
IVE might have been over- or underestimated.
Various studies suggest that ILI test-negative controls represent 
the source population of influenza cases seen at GPs offices and 
that the study design adjusts for propensity to seek care. This 
would mean that the propensity to seek care is equal between ILI 
patients who test positive and those testing negative for influenza. 
Our results indicate that in three out of the five studies, the delay 
between onset of symptoms and swabbing was shorter for cases 
than for test-negative controls. Similar results were found in the 
Wisconsin study [3]. This may indicate a different health-seeking 
behaviour or a different severity of ILI in cases and in controls. 
Health-seeking behaviour of ILI cases and ILI test-negative controls 
should be further studied and compared.
To further assess the representativity of test-negative controls, 
we measured the vaccine coverage in other potential control groups. 
The vaccine coverage differed by control group (test-negative 
controls, non-ILI GP controls, community controls) and between 
countries with no specific pattern.  This could suggest that the 
source population of influenza cases consulting a GP may be country 
specific. In general, the vaccine coverage in the community or in 
the GPs catchment area was lower than the vaccine coverage of GP 
clients indicating that community controls do not represent a good 
control group for medically-attended ILI influenza cases. In a recent 
study in Wisconsin, VE for laboratory confirmed medically attended-
ILI was estimated for three seasons using two control groups: test-
negative controls and controls randomly selected from individuals 
in the source population who did not have a clinical encounter for 
acute respiratory illness prior to the week of recruitment [3]. In 
the three seasons, the vaccination coverage of the test-negative 
controls was higher than among the other controls.
    
We took into account the main confounding factors identified 
in the literature. Most of them were based on patients´ report for 
which validity is unknown. The pooled crude and adjusted IVE were 
similar suggesting a low distortion of effect due to confounding. 
In our study, a small proportion of ILI patients had indicators of 
frailty (4.3% had poor functional status and 6.4% were hospitalised 
in the previous year). Elderly ILI patients consulting GPs at their 
office may have a better health status than those not consulting. 
Therefore, functional status and severity may not be relevant 
confounding factors within this study population and study design. 
Our results may also reflect that using specific outcomes decrease 
the amount of confounding observed [5,7]. In Canada, using the 
same study design, IVE did not change when adjusting for chronic 
diseases [20]. 
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The excellent collaboration between the study teams made the 
pooling of data from the five studies possible. Pooling increased 
the precision of the estimates. Given the small samples sizes of the 
individual studies, we used a one-stage pooling model that assumes 
that the effect of the exposure (the seasonal vaccine) and the 
effect of the covariates are the same in all the studies. We do not 
know if the difference in virus circulation in the various countries 
and a potential different health-seeking behaviour may violate 
this assumption. The pooled estimates of the pilot phase have to 
be interpreted with caution as heterogeneity between studies may 
exist. Futhermore, different vaccine brands were used. However, 
the aim of I-MOVE is not to guide the Member States in deciding 
which seasonal vaccine to purchase. In order to assess VE for the 
various vaccine brands, the sample size would have to be increased 
significantly. The definitions of some covariates were not exactly 
the same in the different studies. Tests for interaction between 
study and covariates did not suggest the presence of heterogeneity. 
However, the small sample size may have led to an insufficient 
power to detect heterogeneity. 
Conclusions 
In 2008-9 the match between the seasonal influenza vaccine 
and the predominant circulating strains was good and the IVE in 
the elderly relatively high. Our results suggest that GP based case-
control studies using test-negative controls to estimate seasonal 
IVE against laboratory-confirmed medically- attended influenza, 
are feasible in Europe. The use of a laboratory confirmed outcome 
may reduce the magnitude of confounding. If other studies confirm 
this, the number of confounders documented may be reduced, thus 
simplifying the data collection. The representativity of test-negative 
controls should be further evaluated. 
Pooling of country specific data is needed to have early seasonal 
or pandemic VE estimates and to increase the precision of the 
estimates for subgroup analysis. In 2009-10 we will increase the 
sample size, by increasing the number of countries participating in 
the study and including more GPs per country. The larger sample 
size will allow the use of a two-stage model that better takes into 
account the potential heterogeneity between studies [18,21]. The 
studies will use common definitions for all variables to minimise 
heterogeneity between studies. During H1N1 influenza pandemic, 
interim analyses will be conducted in different periods according 
to the available sample size. The timing for conducting each of 
the interim analyses will depend on the time necessary to reach 
the appropriate sample size. This will depend mainly on the ILI 
incidence, the influenza incidence and the vaccination coverage.
The suitability of the case-control studies based on sentinel 
GPs to measure pandemic IVE will depend on the vaccination and 
control strategy. If pandemic cases are seen by the sentinel GPs 
and GPs have the possibility to ascertain patient vaccination status, 
then the case-control design piloted in 2008-9 would be adequate 
to estimate pandemic VE. All age and risk groups targeted by the 
vaccine should be included in the study. The design will be adapted 
to reduce the GPs‘ workload by simplifying the questionnaire and 
revising the procedure to select patients to swab.
Acknowledgements
The I-MOVE (influenza: monitoring vaccine effectiveness in Europe) 
programme has been funded by the European Centre for Disease 
Prevention and Control (ECDC) since 2007.
- Denmark: A H Christiansen, LP Nielsen, S Glismann, K Mølbak and the 
interviewers
- Hungary: Z Molnár, KJ Horváth, K Kaszás, M Rózsa, Á Csohán
- Portugal: M Barreto, I Batista, H Rebelo Andrade, LA Santos
- Romania: V Alexandrescu, C Sbarcea, A Baetel and the epidemiologists 
from Maramures, Iasi, Dolj, Calarasi, Constanta, Timisoara, Tulcea
- Spain: S de Mateo, S. Jiménez, I Salmeán (National Centre of 
Epidemiology), F Pozo, I Casas, P Pérez Breña (National Centre of 
Microbiology); A. Galmés Truyols, J Vanrell Berga (Influenza Sentinel 
network of Baleares); M Gutierrez Pérez, T Vega Alonso (Influenza 
Sentinel network of Castilla y León); A Martinez Mateo, N Torner Gracia 
(Influenza Sentinel network of Cataluña); JM Ramos Aceitero, MC Serraro 
Martin (Influenza Sentinel network of Extremadura); M García Cenoz, J 
Castilla Catalán (Influenza Sentinel network of Navarra); JM Altzibar 
Arotzena, JM Arteagoitia Axpe (Influenza Sentinel network of País Vasco); 
C Quiñones Rubio, ME Lezaún Larumbe, M Perucha González (Influenza 
Sentinel network of La Rioja).
-All participating GPs in Denmark, Hungary, Portugal, Romania, and 
Spain.
*Erratum: The x-axis in Figure 1 indicated the wrong weeks and this was corrected 
on 6 November 2009.
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